Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for IONS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 1991. Start Trial.
Date Value
December 31, 2025 913.18M
December 31, 2024 901.53M
December 31, 2023 899.62M
December 31, 2022 833.15M
December 31, 2021 643.45M
December 31, 2020 535.08M
December 31, 2019 465.17M
December 31, 2018 413.36M
December 31, 2017 374.00M
December 31, 2016 341.78M
December 31, 2015 317.50M
December 31, 2014 239.51M
December 31, 2013 181.57M
December 31, 2012 157.64M
December 31, 2011 155.50M
December 31, 2010 143.66M
December 31, 2009 134.62M
December 31, 2008 106.44M
Date Value
December 31, 2007 92.64M
December 31, 2006 80.57M
December 31, 2005 72.78M
December 31, 2004 106.30M
December 31, 2003 104.71M
December 31, 2002 113.77M
December 31, 2001 83.74M
December 31, 2000 57.01M
December 31, 1999 66.41M
December 31, 1998 57.94M
December 31, 1997 52.76M
December 31, 1996 43.02M
December 31, 1995 30.36M
December 31, 1994 22.61M
December 31, 1993 22.37M
December 31, 1992 21.63M
December 31, 1991 11.44M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 1.320B
Biogen, Inc. 1.481B
BridgeBio Pharma, Inc. 451.95M
Vertex Pharmaceuticals, Inc. 3.754B
Arrowhead Pharmaceuticals, Inc. 585.26M